MX2021000071A - Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. - Google Patents
Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.Info
- Publication number
- MX2021000071A MX2021000071A MX2021000071A MX2021000071A MX2021000071A MX 2021000071 A MX2021000071 A MX 2021000071A MX 2021000071 A MX2021000071 A MX 2021000071A MX 2021000071 A MX2021000071 A MX 2021000071A MX 2021000071 A MX2021000071 A MX 2021000071A
- Authority
- MX
- Mexico
- Prior art keywords
- pridopidine
- subject
- cognitive function
- disease
- treating alzheimer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
Abstract
Esta invención proporciona un método para mejorar la función cognitiva en un sujeto, que comprende administrar periódicamente al sujeto una cantidad de pridopidina o una sal farmacéuticamente aceptable de la misma efectiva para mejorar la función cognitiva en el sujeto. La invención también proporciona un método para tratar un sujeto que padece de enfermedad de Alzheimer, que comprende administrar periódicamente al sujeto una composición farmacéutica que comprende una cantidad de pridopidina o una sal farmacéuticamente aceptable de la misma efectiva para tratar al sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562120771P | 2015-02-25 | 2015-02-25 | |
US201562186221P | 2015-06-29 | 2015-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021000071A true MX2021000071A (es) | 2021-03-25 |
Family
ID=56689699
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017010982A MX2017010982A (es) | 2015-02-25 | 2016-02-24 | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. |
MX2021000071A MX2021000071A (es) | 2015-02-25 | 2017-08-25 | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017010982A MX2017010982A (es) | 2015-02-25 | 2016-02-24 | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. |
Country Status (13)
Country | Link |
---|---|
US (1) | US10603311B2 (es) |
EP (4) | EP3590512A1 (es) |
JP (2) | JP6887952B2 (es) |
AU (2) | AU2016222796B2 (es) |
CA (1) | CA2977264C (es) |
DK (1) | DK3261721T3 (es) |
ES (1) | ES2930628T3 (es) |
HU (1) | HUE060353T2 (es) |
IL (2) | IL254030B (es) |
MX (2) | MX2017010982A (es) |
PL (1) | PL3261721T3 (es) |
TW (1) | TW201639570A (es) |
WO (1) | WO2016138130A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2810092A1 (en) | 2010-09-03 | 2012-03-08 | IVAX International GmbH | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
KR102316933B1 (ko) | 2013-06-21 | 2021-10-26 | 프리레니아 뉴로테라퓨틱스 엘티디. | 헌팅턴병 치료를 위한 프리도피딘의 용도 |
TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
US11471449B2 (en) * | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
HUE060353T2 (hu) * | 2015-02-25 | 2023-02-28 | Prilenia Neurotherapeutics Ltd | Pridopidin alkalmazása memória javítására |
AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
US11738012B2 (en) | 2016-02-24 | 2023-08-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
MX2019002190A (es) | 2016-08-24 | 2019-09-11 | Prilenia Therapeutics Dev Ltd | Uso de pridopidina para tratar distonías. |
EP3504187A4 (en) * | 2016-08-24 | 2020-05-06 | Prilenia Neurotherapeutics Ltd. | USE OF PRIDOPIDINE FOR THE TREATMENT OF FUNCTIONAL DECLINE |
WO2018053287A1 (en) * | 2016-09-15 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of anxiety and depression |
US20210093622A1 (en) * | 2016-09-15 | 2021-04-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of anxiety and depression |
CA3036984C (en) * | 2016-09-16 | 2023-07-18 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating rett syndrome |
CN110505902B (zh) * | 2017-01-20 | 2022-11-11 | 普瑞尼亚神经治疗有限公司 | 普利多匹定用于治疗脆性x综合征的应用 |
EP3668509B1 (en) | 2017-08-14 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | Method of treating amyotrophic lateral sclerosis with pridopidine |
CA3073568A1 (en) | 2017-08-30 | 2019-03-07 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
CN111343982A (zh) | 2017-09-08 | 2020-06-26 | 普瑞尼亚神经治疗有限公司 | 用于治疗药物诱发的异动症的普利多匹定 |
EP3920924A4 (en) * | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | LOW DOSE PRIDOPIDINE FOR TREATING PARKINSON'S DISEASE AND OTHER PARKINSONISM-ASSOCIATED DISEASES |
EP3937937A4 (en) * | 2019-03-15 | 2022-11-23 | Prilenia Neurotherapeutics Ltd. | TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH MITOCHONDRIA, INCLUDING THEIR SYMPTOMS USING PRIDOPIDINE |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2157204T3 (es) | 1991-04-17 | 2001-08-16 | Upjohn Co | Derivados de (s)-3-fenilpiperidina sustituidos, su preparacion y uso como antagonistas de autorreceptores de dopamina. |
US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
SE9702716D0 (sv) * | 1997-07-15 | 1997-07-15 | Ross Nicholas Waters | Substituted phenylazacycloalkanes in the treatment of cognitive disorders |
SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
JP4847320B2 (ja) * | 2004-02-20 | 2011-12-28 | 大日本住友製薬株式会社 | 統合失調症の記憶・学習機能障害治療薬のinvivoスクリーニング方法 |
WO2006040155A1 (en) | 2004-10-13 | 2006-04-20 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
EP1815857A1 (en) | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
PT2146961E (pt) | 2007-04-12 | 2014-04-30 | Ivax Int Gmbh | Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados |
EP2254564A1 (en) | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
DK2421519T3 (en) | 2009-04-23 | 2017-02-06 | Univ Zuerich | NMDA RECEPTOR BLOCKERS FOR THE TREATMENT OF SEAL CELL ANAEMS |
EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
US8849866B2 (en) | 2010-02-22 | 2014-09-30 | Infosys Limited | Method and computer program product for creating ordered data structure |
WO2011107583A1 (en) | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
PL2578212T3 (pl) | 2010-05-24 | 2017-01-31 | Farmalider Sa | Związek hamujący aktywację enzymu Erk 1/2 do zastosowania w leczeniu chorób neurodegeneracyjnych |
CA2810092A1 (en) | 2010-09-03 | 2012-03-08 | IVAX International GmbH | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
UY34278A (es) * | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
EA023462B1 (ru) | 2011-09-07 | 2016-06-30 | Тева Фармасьютикалз Интернэшнл Гмбх | Полиморфная форма гидрохлорида придопидина |
US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
CA2869145A1 (en) | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
US20140088140A1 (en) * | 2012-09-27 | 2014-03-27 | Teva Pharmaceutical Industries, Ltd. | Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
EP2900226A4 (en) | 2012-09-27 | 2016-03-30 | Teva Pharma | COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE |
DK3004080T3 (da) | 2013-06-04 | 2019-01-02 | Acturum Real Estate Ab | Triazolforbindelser og deres anvendelse som gamma-sekretase-modulatorer |
KR102316933B1 (ko) * | 2013-06-21 | 2021-10-26 | 프리레니아 뉴로테라퓨틱스 엘티디. | 헌팅턴병 치료를 위한 프리도피딘의 용도 |
US20150202302A1 (en) | 2014-01-22 | 2015-07-23 | IVAX International GmbH | Modified release formulations of pridopidine |
TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
HUE060353T2 (hu) * | 2015-02-25 | 2023-02-28 | Prilenia Neurotherapeutics Ltd | Pridopidin alkalmazása memória javítására |
AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
CA2993183A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
WO2017048457A1 (en) | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
MX2019002190A (es) | 2016-08-24 | 2019-09-11 | Prilenia Therapeutics Dev Ltd | Uso de pridopidina para tratar distonías. |
EP3504187A4 (en) | 2016-08-24 | 2020-05-06 | Prilenia Neurotherapeutics Ltd. | USE OF PRIDOPIDINE FOR THE TREATMENT OF FUNCTIONAL DECLINE |
-
2016
- 2016-02-24 HU HUE16756274A patent/HUE060353T2/hu unknown
- 2016-02-24 EP EP19191835.8A patent/EP3590512A1/en not_active Withdrawn
- 2016-02-24 JP JP2017545405A patent/JP6887952B2/ja active Active
- 2016-02-24 PL PL16756274.3T patent/PL3261721T3/pl unknown
- 2016-02-24 WO PCT/US2016/019357 patent/WO2016138130A1/en active Application Filing
- 2016-02-24 DK DK16756274.3T patent/DK3261721T3/da active
- 2016-02-24 EP EP16756274.3A patent/EP3261721B1/en active Active
- 2016-02-24 MX MX2017010982A patent/MX2017010982A/es unknown
- 2016-02-24 US US15/052,368 patent/US10603311B2/en active Active
- 2016-02-24 EP EP21153340.1A patent/EP3854785A1/en not_active Ceased
- 2016-02-24 EP EP23198399.0A patent/EP4282479A3/en active Pending
- 2016-02-24 CA CA2977264A patent/CA2977264C/en active Active
- 2016-02-24 ES ES16756274T patent/ES2930628T3/es active Active
- 2016-02-24 AU AU2016222796A patent/AU2016222796B2/en active Active
- 2016-02-25 TW TW105105721A patent/TW201639570A/zh unknown
-
2017
- 2017-08-16 IL IL254030A patent/IL254030B/en unknown
- 2017-08-25 MX MX2021000071A patent/MX2021000071A/es unknown
-
2021
- 2021-01-07 JP JP2021001418A patent/JP7210620B2/ja active Active
- 2021-03-12 AU AU2021201583A patent/AU2021201583B2/en active Active
- 2021-09-30 IL IL286888A patent/IL286888A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL254030A0 (en) | 2017-10-31 |
AU2021201583B2 (en) | 2022-04-07 |
IL286888A (en) | 2021-10-31 |
MX2017010982A (es) | 2017-11-20 |
PL3261721T3 (pl) | 2022-12-27 |
EP4282479A3 (en) | 2024-02-21 |
WO2016138130A1 (en) | 2016-09-01 |
JP6887952B2 (ja) | 2021-06-16 |
EP3261721A4 (en) | 2018-08-08 |
AU2016222796A1 (en) | 2017-10-05 |
US20160243098A1 (en) | 2016-08-25 |
EP3854785A1 (en) | 2021-07-28 |
TW201639570A (zh) | 2016-11-16 |
ES2930628T3 (es) | 2022-12-20 |
AU2021201583A1 (en) | 2021-04-01 |
EP3590512A1 (en) | 2020-01-08 |
JP2018506569A (ja) | 2018-03-08 |
CA2977264C (en) | 2021-12-07 |
JP2021073206A (ja) | 2021-05-13 |
EP4282479A2 (en) | 2023-11-29 |
AU2016222796B2 (en) | 2021-07-15 |
CA2977264A1 (en) | 2016-09-01 |
DK3261721T3 (da) | 2022-11-28 |
EP3261721A1 (en) | 2018-01-03 |
HUE060353T2 (hu) | 2023-02-28 |
EP3261721B1 (en) | 2022-09-14 |
US10603311B2 (en) | 2020-03-31 |
JP7210620B2 (ja) | 2023-01-23 |
IL254030B (en) | 2022-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
MX2018002990A (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos. | |
MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
PH12017500493A1 (en) | Combination therapy | |
EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
IN2015DN03219A (es) | ||
MX337614B (es) | Tratamiento de lupus nefritis usando laquinimod. | |
MX342001B (es) | Tratamiento de artritis por lupus usando laquinimod. | |
MX2019012884A (es) | Terapia de combinacion. | |
MX2021002321A (es) | Nuevos metodos. | |
PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
MX370953B (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
MX2016008953A (es) | Composiciones farmaceuticas que comprenden i5-hidroxi-eicosa- 5,8,11,13,17-pentaenoico ( 15-hepe ) y metodos para tratar el asma y trastornos pulmonares que usan las mismas. | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
MX2019004200A (es) | Terapia de combinacion. | |
MX2016008968A (es) | Compuestos organicos. | |
PH12018500682A1 (en) | Oxa-diazaspiro compounds having activity against pain | |
GB201115977D0 (en) | Neurodevelopmental disorders | |
MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
MX2014013491A (es) | Metodos para mantener, tratar o mejorar la funcion cognitiva. | |
NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders |